Cargando…

CD44v3 is a marker of invasive cancer stem cells driving metastasis in gastric carcinoma

BACKGROUND: Cancer stem cells (CSCs) are at the origin of tumour initiation and progression in gastric adenocarcinoma (GC). However, markers of metastasis-initiating cells remain unidentified in GC. In this study, we characterized CD44 variants expressed in GC and evaluated the tumorigenic and metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Giraud, Julie, Seeneevassen, Lornella, Rousseau, Benoit, Bouriez, Damien, Sifré, Elodie, Giese, Alban, Nguyen, Tra Ly, Tiffon, Camille, Lippi, Yannick, Azzi-Martin, Lamia, Pannequin, Julie, Ménard, Armelle, Bessède, Emilie, Staedel, Cathy, Mégraud, Francis, Belleannée, Geneviève, Lehours, Philippe, Gronnier, Caroline, Dubus, Pierre, Varon, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950191/
https://www.ncbi.nlm.nih.gov/pubmed/36528833
http://dx.doi.org/10.1007/s10120-022-01357-y
Descripción
Sumario:BACKGROUND: Cancer stem cells (CSCs) are at the origin of tumour initiation and progression in gastric adenocarcinoma (GC). However, markers of metastasis-initiating cells remain unidentified in GC. In this study, we characterized CD44 variants expressed in GC and evaluated the tumorigenic and metastatic properties of CD44v3+ cells and their clinical significance in GC patients. METHODS: Using GC cell lines and patient-derived xenografts, we evaluated CD44+ and CD44v3+ GC cells molecular signature and their tumorigenic, chemoresistance, invasive and metastatic properties, and expression in patients-derived tissues. RESULTS: CD44v3+ cells, which represented a subpopulation of CD44+ cells, were detected in advanced preneoplastic lesions and presented CSCs chemoresistance and tumorigenic properties in vitro and in vivo. Molecular and functional analyses revealed two subpopulations of gastric CSCs: CD44v3+ CSCs with an epithelial-mesenchymal transition (EMT)-like signature, and CD44+/v3– CSCs with an epithelial-like signature; both were tumorigenic but CD44v3+ cells showed higher invasive and metastatic properties in vivo. CD44v3+ cells detected in the primary tumours of GC patients were associated with a worse prognosis. CONCLUSION: CD44v3 is a marker of a subpopulation of CSCs with metastatic properties in GC. The identification of metastasis-initiating cells in GC represents a major advance for further development of anti-metastatic therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10120-022-01357-y.